VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
GOVX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
GOVXGeoVax Labs, Inc.
$0.16$151342
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
GOVX logo

GeoVax Labs, Inc.

GOVX
NASDAQ · Vaccines & Infectious Disease
$0.16
At close - Nov 6, 4:00 PM EST - USD
Market Cap$151342
P/E-0.0x
52W High$13.44
Volume341.85K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Persistent Cash Burn Threatens Clinical Development Continuity

GeoVax Labs faces a precarious outlook as its reliance on volatile, non-recurring grant revenue has led to a complete cessation of income in recent quarters. The company's heavy fixed-cost structure, characterized by quarterly R&D expenditures often exceeding $5 million, continues to erode its limited capital base.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

GOVX price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

8/12 Beats

EPS beat 8 of last 12 quarters

02

Valuation risk

-100% Peers

P/E is 100% below peer median

03

Market leadership

RS 2 · Lag

Laggard (Underperforming 98% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Oct 27

Market performance

Price History →

Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
GOVX-96.95%
S&P 500 (^GSPC)+7.63%
1-Year Return
GOVX-98.79%
S&P 500 (^GSPC)+9.69%
3-Year Return
GOVX-99.92%
S&P 500 (^GSPC)+68.76%
5-Year Return
GOVX-99.99%
S&P 500 (^GSPC)+56.80%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$2M-37.1% YoY
Net income FY25
-$21M+14.1% YoY
Free cash flow FY25
-$22M+12.9% YoY
Operating margin FY25
-869.3%-233.5 pts YoY
ROIC (FY25)-2887.4%
Avg ROIC 5Y-2887.4%
ROE (TTM)-743.7%
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate8/12 (67%)
Revenue Beat Rate3/12 (75%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026Latest
Jul 27, 2026
-$0.97+55.1%
vs -$2.16
—
vs —
Q2 2026
May 14, 2026
-$2.62-63.7%
vs -$1.60
—
vs —
Q2 2026
Apr 2, 2026
-$2.29+51.3%
vs -$4.71
—
vs $1M
Q4 2025
Nov 13, 2025
-$7.75-29.2%
vs -$6.00
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

2 Stories
Defense World·Oct 21, 2026
Reviewing GeoVax Labs (NASDAQ:GOVX) & 4D Molecular Therapeutics (NASDAQ:FDMT)

GeoVax Labs (NASDAQ: GOVX - Get Free Report) and 4D Molecular Therapeutics (NASDAQ: FDMT - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations. Profitability This table compares GeoVax Labs

Defense World·Oct 11, 2026
Head to Head Analysis: GeoVax Labs (NASDAQ:GOVX) vs. Lisata Therapeutics (NASDAQ:LSTA)

Lisata Therapeutics (NASDAQ: LSTA - Get Free Report) and GeoVax Labs (NASDAQ: GOVX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Analyst Ratings This is a summary of

Filtered for GeoVax Labs, Inc.More Headlines
04

Compare before deciding

Benchmark GOVX against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for GeoVax Labs, Inc. (GOVX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
GOVX logoGOVXGeoVax Labs, Inc.Current
$0.16$151.34K-0.04-37.06%-862.34%-743.66%—
NVAX logoNVAXNovavax, Inc.
$10.78$1.77B-23.1764.69%-18.64%——
IOVA logoIOVAIovance Biotherapeutics, Inc.
$8.04$3.59B-16.6260.6%-58.19%-29.71%—
SIGA logoSIGASIGA Technologies, Inc.
$3.10$222.34M-80.94-31.8%-5.14%-1.53%19.42%
AGEN logoAGENAgenus Inc.
$7.15$297.74M21.1910.37%20.98%——
IMVT logoIMVTImmunovant, Inc.
$30.53$6.3B-11.66—-7585.86%-69.59%—

Compare GOVX vs Peers

GeoVax Labs, Inc. (GOVX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NVAX

Most directly comparable listed peer for GOVX.

Scale Benchmark

vs MRK

Larger-name benchmark to compare GOVX against a more recognizable public peer.

Peer Set

Compare Top 5

vs NVAX, IOVA, SIGA, AGEN

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

GOVX SEC Filings & Documents

GeoVax Labs, Inc. (GOVX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Jul 27, 2026·SEC

Material company update

Jul 10, 2026·SEC

Material company update

Jun 17, 2026·SEC

10-K Annual Reports

2
FY 2026

Apr 15, 2026·SEC

FY 2025

Mar 27, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Jul 27, 2026·SEC

FY 2026

May 14, 2026·SEC

FY 2025

Nov 13, 2025·SEC

Get notified when GOVX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

GOVX Frequently Asked Questions

GeoVax Labs, Inc. (GOVX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is GeoVax Labs, Inc.'s revenue?

GeoVax Labs, Inc. (GOVX) reported $2.5M in revenue in fiscal year 2025. That is 2550% more than the $0.1M of fiscal year 1996.

How fast is GeoVax Labs, Inc. growing?

GeoVax Labs, Inc. (GOVX) revenue fell by 100.0% over the trailing twelve months, compared with the twelve months before.

Is GOVX profitable?

No. GeoVax Labs, Inc. (GOVX) reported a net loss of $20.4M over the trailing twelve months.

Dividend & Returns
What is GOVX's return on equity?

GeoVax Labs, Inc. (GOVX) had a return on equity (ROE) of -743.7% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is GeoVax Labs, Inc.'s free cash flow?

GeoVax Labs, Inc. (GOVX) had negative free cash flow of $18.4M over the trailing twelve months.

What if you invested $1,000 in GOVX back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →